HDAC inhibition amplifies gap junction communication in neural progenitors: Potential for cell-mediated enzyme prodrug therapy

Experimental Cell Research

Volumn 313, Issue 13, 2007, Pages 2958-2967

  Khan, Zahidul ^a   Akhtar, Monira ^a   Asklund, Thomas ^a   Juliusson, Bengt ^b   Almqvist, Per M ^a,b,c   Ekström, Tomas J ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NsGene AS   (Denmark)

^c ZGene AS   (Denmark)

Author keywords

4 Phenylbutyrate; Bystander effect; Connexin 43; Gap junction; Gene therapy; Histone deacetylases; Neural progenitor cell

Indexed keywords

4 PHENYLBUTYRIC ACID; CONNEXIN 43; FLUORESCENT DYE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PRODRUG; RECOMBINANT PROTEIN; SERINE; TRICHOSTATIN A;

ARTICLE; BYSTANDER EFFECT; CELL CULTURE; CELL DIFFERENTIATION; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL TRANSPORT; CONTROLLED STUDY; EMBRYO; ENZYME INHIBITION; ENZYME PRODRUG THERAPY; GAP JUNCTION; GENE TARGETING; GENE THERAPY; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MESENCEPHALON; MOLECULAR WEIGHT; NERVE CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STEM CELL; WESTERN BLOTTING;

ANIMALIA;

EID: 34547154713     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2007.05.004     Document Type: Article

References (39)

1. Kleihues P., and Cavenee W.K. Pathology and Genetics of Tumors of Nervous System (2000), International Agency for Research on Cancer Press, Lyon
2. Maher E.A., Furnari F.B., Bachoo R.M., Rowitch D.H., Louis D.N., Cavenee W.K., and DePinho R.A. Malignant Glioma: Genetics and Biology of a Grave Matter. Genes Dev. 15 (2001) 1311-1333
3. E.R. Laws, Jr., Central nervous system tumors: what have we learned and where are we heading? CA Cancer J. Clin. 48 (1998) 327-329, 322.
4. Costantini L.C., Bakowska J.C., Breakefield X.O., and Isacson O. Gene therapy in the CNS. Gene Ther. 7 (2000) 93-109
5. Basilion J.P., Ichikawa T., and Chiocca E.A. Gene therapy of brain tumors: problems presented by physiological barriers. Neurosurg. Focus 8 (2000)
6. Lawler S.E., Peruzzi P.P., and Chiocca E.A. Genetic strategies for brain tumor therapy. Cancer Gene Ther. 13 (2006) 225-233
7. Holland E.C. Glioblastoma multiforme: the terminator. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 6242-6244
8. Aboody K.S., Brown A., Rainov N.G., Bower K.A., Liu S., Yang W., Small J.E., Herrlinger U., Ourednik V., Black P.M., Breakefield X.O., and Snyder E.Y. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 12846-12851
9. Glass R., Synowitz M., Kronenberg G., Walzlein J.H., Markovic D.S., Wang L.P., Gast D., Kiwit J., Kempermann G., and Kettenmann H. Glioblastoma-induced attraction of endogenous neural precursor cells is associated with improved survival. J. Neurosci. 25 (2005) 2637-2646
10. Brown A.B., Yang W., Schmidt N.O., Carroll R., Leishear K.K., Rainov N.G., Black P.M., Breakefield X.O., and Aboody K.S. Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. Hum. Gene Ther. 14 (2003) 1777-1785
11. Muller F.J., Snyder E.Y., and Loring J.F. Gene therapy: can neural stem cells deliver?. Nat. Rev., Neurosci. 7 (2006) 75-84
12. Benedetti S., Pirola B., Pollo B., Magrassi L., Bruzzone M.G., Rigamonti D., Galli R., Selleri S., Di Meco F., De Fraja C., Vescovi A., Cattaneo E., and Finocchiaro G. Gene therapy of experimental brain tumors using neural progenitor cells. Nat. Med. 6 (2000) 447-450
13. Ehtesham M., Kabos P., Gutierrez M.A., Chung N.H., Griffith T.S., Black K.L., and Yu J.S. Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 62 (2002) 7170-7174
14. Ehtesham M., Kabos P., Kabosova A., Neuman T., Black K.L., and Yu J.S. The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res. 62 (2002) 5657-5663
15. Yang S.Y., Liu H., and Zhang J.N. Gene therapy of rat malignant gliomas using neural stem cells expressing IL-12. DNA Cell Biol. 23 (2004) 381-389
16. Li S., Tokuyama T., Yamamoto J., Koide M., Yokota N., and Namba H. Bystander effect-mediated gene therapy of gliomas using genetically engineered neural stem cells. Cancer Gene Ther. 12 (2005) 600-607
17. Dilber M.S., Abedi M.R., Christensson B., Bjorkstrand B., Kidder G.M., Naus C.C., Gahrton G., and Smith C.I. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res. 57 (1997) 1523-1528
18. Zhang W., Couldwell W.T., Simard M.F., Song H., Lin J.H., and Nedergaard M. Direct gap junction communication between malignant glioma cells and astrocytes. Cancer Res. 59 (1999) 1994-2003
19. Asklund T., Appelskog I.B., Ammerpohl O., Langmoen I.A., Dilber M.S., Aints A., Ekström T.J., and Almqvist P.M. Gap junction-mediated bystander effect in primary cultures of human malignant gliomas with recombinant expression of the HSVtk gene. Exp. Cell Res. 284 (2003) 185-195
20. Bennett M.V., Contreras J.E., Bukauskas F.F., and Saez J.C. New roles for astrocytes: gap junction hemichannels have something to communicate. Trends Neurosci. 26 (2003) 610-617
21. Alexander D.B., and Goldberg G.S. Transfer of biologically important molecules between cells through gap junction channels. Curr. Med. Chem. 10 (2003) 2045-2058
22. Bruzzone R., White T.W., and Paul D.L. Connections with connexins: the molecular basis of direct intercellular signaling. Eur. J. Biochem. 238 (1996) 1-27
23. Burrows F.J., Gore M., Smiley W.R., Kanemitsu M.Y., Jolly D.J., Read S.B., Nicholas T., and Kruse C.A. Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells. Cancer Gene Ther. 9 (2002) 87-95
24. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev., Drug Discov. 1 (2002) 287-299
25. Marin-Husstege M., Muggironi M., Liu A., and Casaccia-Bonnefil P. Histone deacetylase activity is necessary for oligodendrocyte lineage progression. J. Neurosci. 22 (2002) 10333-10345
26. Lee J.H., Hart S.R., and Skalnik D.G. Histone deacetylase activity is required for embryonic stem cell differentiation. Genesis 38 (2004) 32-38
27. De Felice L., Tatarelli C., Mascolo M.G., Gregorj C., Agostini F., Fiorini R., Gelmetti V., Pascale S., Padula F., Petrucci M.T., Arcese W., and Nervi C. Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res. 65 (2005) 1505-1513
28. Asklund T., Appelskog I.B., Ammerpohl O., Ekström T.J., and Almqvist P.M. Histone deacetylase inhibitor 4-phenylbutyrate modulates glial fibrillary acidic protein and connexin 43 expression, and enhances gap-junction communication, in human glioblastoma cells. Eur. J. Cancer 40 (2004) 1073-1081
29. Ammerpohl O., Thormeyer D., Khan Z., Appelskog I.B., Gojkovic Z., Almqvist P.M., and Ekström T.J. HDACi phenylbutyrate increases bystander killing of HSV-tk transfected glioma cells. Biochem. Biophys. Res. Commun. 324 (2004) 8-14
30. Ponten J., and Macintyre E.H. Long term culture of normal and neoplastic human glia. Acta Pathol. Microbiol. Scand. 74 (1968) 465-486
31. Westermark B., Ponten J., and Hugosson R. Determinants for the establishment of permanent tissue culture lines from human gliomas. Acta Pathol. Microbiol. Scand., A 81 (1973) 791-805
32. Villa A., Snyder E.Y., Vescovi A., and Martinez-Serrano A. Establishment and properties of a growth factor-dependent, perpetual neural stem cell line from the human CNS. Exp. Neurol. 161 (2000) 67-84
33. Uhl M., Weiler M., Wick W., Jacobs A.H., Weller M., and Herrlinger U. Migratory neural stem cells for improved thymidine kinase-based gene therapy of malignant gliomas. Biochem. Biophys. Res. Commun. 328 (2005) 125-129
34. Ekström T.J., Khan Z., Gojkovic Z., Willer M., Almqvist P.M., and Novel A. Thymidine kinase in enhanced gap junction mediated suicide gene therapy. Mol. Ther. 11 Suppl. 1 (2005) 119
35. Phuphanich S., Baker S.D., Grossman S.A., Carson K.A., Gilbert M.R., Fisher J.D., and Carducci M.A. Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro-oncol. 7 (2005) 177-182
36. Mercuri E., Bertini E., Messina S., Solari A., D'Amico A., Angelozzi C., Battini R., Berardinelli A., Boffi P., Bruno C., Cini C., Colitto F., Kinali M., Minetti C., Mongini T., Morandi L., Neri G., Orcesi S., Pane M., Pelliccioni M., Pini A., Tiziano F.D., Villanova M., Vita G., and Brahe C. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology 68 (2007) 51-55
37. Lampe P.D., and Lau A.F. The effects of connexin phosphorylation on gap junctional communication. Int. J. Biochem. Cell Biol. 36 (2004) 1171-1186
38. Reynhout J.K., Lampe P.D., and Johnson R.G. An activator of protein kinase C inhibits gap junction communication between cultured bovine lens cells. Exp. Cell Res. 198 (1992) 337-342
39. Rosenqvist N., Hard Af Segerstad C., Samuelsson C., Johansen J., and Lundberg C., Activation of silenced transgene expression in neural precursor cell lines by inhibitors of histone deacetylation. J. Gene Med. 4 (2002) 248-257